Skip to search formSkip to main contentSkip to account menu

GSK 1120212

Known as: GSK-1120212, GSK1120212, MEK Inhibitor GSK1120212 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

trametinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
2017
2017
Anti-Melanoma Activities of Haspin Inhibitor CHR-6494 Deployed as a Single Agent or in a Synergistic Combination with MEK Inhibitor
Background: Melanoma is a heterogeneous malignancy that presents an immense challenge in therapeutic development. Recent… 
2017
2017
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients… 
2016
2016
ERK Plays a Role in Chromosome Alignment and Participates in M‐Phase Progression
Cell division, a prerequisite for cell proliferation, is a process in which each daughter cell inherits one complete set of… 
2016
2016
A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma.
e14584 Background: GSK1120212 is a potent and highly selective inhibitor of MEK1, a component of the MAP kinase pathway… 
2015
2015
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
SummaryBackground Trametinib is an inhibitor of MEK1/MEK2 activation and kinase activity. In order to evaluate the safety… 
2014
2014
Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma
Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the treatment of melanoma… 
2014
2014
Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors.
BACKGROUND Vascular endothelial growth factor-targeted kinase inhibitors have emerged as highly promising therapies for… 
2012
2012
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced…
3003 Background: MAPK and PI3K/AKT signaling pathways regulate proliferation, differentiation and cell death in human cancers… 
2012
2012
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with…
3023 Background: Trametinib, an oral MEK1/MEK2 inhibitor, has demonstrated single-agent clinical activity. In vitro studies of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)